{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:21:09Z","timestamp":1790310069427,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.virol.2013.12.029","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T21:01:20Z","timestamp":1389214880000},"page":"243-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Protection of non-human primates against rabies with an adenovirus recombinant vaccine"],"prefix":"10.1016","volume":"450-451","author":[{"given":"Z.Q.","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.C.","family":"Ertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Rupprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2013.12.029_bib1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env Vaccine (IPCAVD 001)","volume":"207","author":"Baden","year":"2012","journal-title":"J. Infectious Dis."},{"key":"10.1016\/j.virol.2013.12.029_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.virol.2013.12.029_bib3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.20506\/rst.15.3.965","article-title":"Field use of a vaccinia-rabies recombinant vaccine for the control of sylvaticrabies in Europe and North America","volume":"15","author":"Brochier","year":"1996","journal-title":"Rev. Sci. Technol."},{"key":"10.1016\/j.virol.2013.12.029_bib4","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.1128\/JVI.00450-10","article-title":"Adenovirus-based vaccines: comparison of vectors from three species of Adenoviridae","volume":"84","author":"Chen","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.12.029_bib5","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.vaccine.2005.03.059","article-title":"Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai children","volume":"24","author":"Chulasugandha","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2013.12.029_bib6","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1016\/j.vaccine.2009.09.034","article-title":"Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines","volume":"27","author":"Franka","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2013.12.029_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/aid.2008.0212","article-title":"Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults","volume":"25","author":"Harro","year":"2009","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.virol.2013.12.029_bib8","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.vaccine.2012.01.048","article-title":"A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity","volume":"30","author":"Hoft","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2013.12.029_bib9","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.vaccine.2009.10.091","article-title":"Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive","volume":"28","author":"Hutnick","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2013.12.029_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7705\/biomedica.v29i2.18","article-title":"Therapy of rabies encephalitis","volume":"29","author":"Jackson","year":"2009","journal-title":"Biom\u00e9dica: revista del Instituto Nacional de Salud"},{"key":"10.1016\/j.virol.2013.12.029_bib11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/jtm.12024","article-title":"The global availability of rabies immune globulin and rabies vaccine in clinics providing direct care to travelers","volume":"20","author":"Jentes","year":"2013","journal-title":"J. Travel Med."},{"key":"10.1016\/j.virol.2013.12.029_bib12","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1016\/j.vaccine.2010.03.039","article-title":"The immune response to rabies virus infection and vaccination","volume":"28","author":"Johnson","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2013.12.029_bib13","first-page":"360","article-title":"Re-evaluating the burden of rabies in Africa and Asia","volume":"83","author":"Knobel","year":"2005","journal-title":"Bull. World Health Organiz."},{"key":"10.1016\/j.virol.2013.12.029_bib14","doi-asserted-by":"crossref","first-page":"e1388","DOI":"10.1371\/journal.pntd.0001388","article-title":"The blueprint for rabies prevention and control: a novel operational toolkit for rabies elimination","volume":"6","author":"Lembo","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.virol.2013.12.029_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0092-1157(75)90061-X","article-title":"Measurement of rabies antibody: comparison of the mouse neutralization test (MNT) with the rapid fluorescent focus inhibition test (RFFIT)","volume":"3","author":"Louie","year":"1975","journal-title":"J. Biol. Stand."},{"key":"10.1016\/j.virol.2013.12.029_bib16","first-page":"14","article-title":"Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine","author":"Malerczyk","year":"2007","journal-title":"J. Travel Med."},{"key":"10.1016\/j.virol.2013.12.029_bib17","unstructured":"Manning, S.E., Rupprecht, C.E., Fishbein, D., Hanlon, C.A., Lumlertdacha, B., Guerra, M., et al., 2008. Human Rabies Prevention\u2014United States, 2008. MMWR. Morbidity and Mortality Weekly Report, 57, 1\u201328."},{"key":"10.1016\/j.virol.2013.12.029_bib18","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1128\/JVI.02497-06","article-title":"Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors","volume":"81","author":"McCoy","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.12.029_bib19","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case\u2013cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2013.12.029_bib20","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.1016\/j.vaccine.2007.10.030","article-title":"Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules","volume":"25","author":"Mercier","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2013.12.029_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.antiviral.2013.03.011","article-title":"Antiviral research","volume":"98","author":"Meslin","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.virol.2013.12.029_bib22","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.virol.2013.12.029_bib23","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.4161\/hv.25203","article-title":"Pre-exposure prophylaxis against rabies in children: Safety of purified chick embryo cell rabies vaccine (Vaxirab N) when administered by intradermal route","volume":"9","author":"Ravish","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virol.2013.12.029_bib24","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1128\/jcm.18.4.968-971.1983","article-title":"Increased immunofluorescent staining of rabies-infected, formalin-fixed brain tissue after pepsin and trypsin digestion","volume":"18","author":"Reid","year":"1983","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.virol.2013.12.029_bib25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.virol.2013.12.029_bib26","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1016\/j.vaccine.2009.09.029","article-title":"Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals","volume":"27","author":"Rupprecht","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2013.12.029_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.virusres.2005.03.017","article-title":"Oral vaccination of dogs with recombinant rabies virus vaccines","volume":"111","author":"Rupprecht","year":"2005","journal-title":"Virus Res."},{"key":"10.1016\/j.virol.2013.12.029_bib28","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/mt.2012.223","article-title":"ChAd63-MVA\u2013vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans","volume":"20","author":"Sheehy","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virol.2013.12.029_bib29","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1016\/j.vaccine.2006.02.027","article-title":"Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity","volume":"24","author":"Suwansrinon","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2013.12.029_bib30","unstructured":"WHO Position Paper. Rabies Vaccines. (2007). Rabies Vaccines. WHO Position Paper. Weekly Epidemiological Record\/Health Section of the Secretariat of the League of Nations, 82, 425\u2013435."},{"key":"10.1016\/j.virol.2013.12.029_bib31","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.1016\/j.vaccine.2009.09.033","article-title":"Poxvirus-vectored vaccines for rabies\u2014a review","volume":"27","author":"Weyer","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2013.12.029_bib32","unstructured":"World Health Organization, 2013. WHO Expert Consultation on Rabies. Second Report. World Health Organization Technical Report Series, 1\u2013139."},{"key":"10.1016\/j.virol.2013.12.029_bib33","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1586\/erv.11.140","article-title":"From brain passage to cell adaptation: the road of human rabies vaccine development","volume":"10","author":"Wu","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.virol.2013.12.029_bib34","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.4049\/jimmunol.162.11.6716","article-title":"Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant","volume":"162","author":"Xiang","year":"1999","journal-title":"J. Immunol. (Baltimore, MD: 1950)"},{"key":"10.1016\/j.virol.2013.12.029_bib35","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/viro.1996.0239","article-title":"A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier","volume":"219","author":"Xiang","year":"1996","journal-title":"Virology"},{"key":"10.1016\/j.virol.2013.12.029_bib36","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1128\/JVI.76.6.2667-2675.2002","article-title":"Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product","volume":"76","author":"Xiang","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.12.029_bib37","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3201\/eid1210.060078","article-title":"Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa","volume":"12","author":"Xiang","year":"2006","journal-title":"Emerg. Infectious Dis."},{"key":"10.1016\/j.virol.2013.12.029_bib38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1517\/14712598.6.1.63","article-title":"Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections","volume":"6","author":"Zhou","year":"2006","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.virol.2013.12.029_bib39","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/nprot.2010.134","article-title":"An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector","volume":"5","author":"Zhou","year":"2010","journal-title":"Nat. Protocols"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682213006922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682213006922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:24:45Z","timestamp":1758587085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682213006922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":39,"alternative-id":["S0042682213006922"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2013.12.029","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protection of non-human primates against rabies with an adenovirus recombinant vaccine","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2013.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}